Research Ethics (Humans, Animals, Sensitive Work)

5.1 Purpose and Scope
This policy sets the minimum ethical requirements for any submission that involves humans, animals, sensitive data or materials, fieldwork, dual-use research, or high-risk methods. It applies to authors, editors, reviewers, and publisher staff across all journals we publish.

5.2 Core Principles

  • Respect for persons, beneficence, and justice.
  • Do no harm and minimize risk; risks must be reasonable in relation to anticipated benefits and scientific value.
  • Independent ethical oversight prior to data collection when required.
  • Transparency and accountability in reporting approvals, consent, and safeguards.

5.3 Human Participants (Non-clinical and Clinical)

  • Ethics approval: Research involving human participants, identifiable data, or biological specimens must have prior approval from an independent ethics committee/IRB or documented exemption. Provide the committee name, approval number (if issued), and date.
  • Informed consent: Obtain and document prospective, informed consent. For minimal-risk secondary analyses of properly de-identified data, justify any consent waiver granted by an ethics body.
  • Privacy and confidentiality: De-identify data to accepted standards. Remove direct identifiers from text, figures, and supplementary files. Use controlled-access repositories for sensitive datasets.
  • Vulnerable groups: Additional safeguards are required for children, older adults with impaired capacity, refugees, detainees, economically disadvantaged persons, and other groups with limited autonomy. Assent and guardian consent are required where applicable.
  • Community and Indigenous data: Respect community review processes, data sovereignty principles, and benefit-sharing agreements. Clearly state permissions and governance arrangements.

5.4 Clinical Trials and Interventional Studies

  • Prospective registration: Register trials in a WHO-recognized public registry before enrolling the first participant, and include the registration ID in the manuscript.
  • Protocol and deviations: Provide access to protocols (or extended methods) and explain deviations from the protocol or pre-registration.
  • Data monitoring and stopping rules: Report oversight arrangements (e.g., DSMB) and any stopping criteria.
  • CONSORT-aligned reporting: Provide participant flow, allocation methods, blinding, outcomes, and harms.

5.5 Use of Human Biological Materials

  • Consent scope: Ensure consent covers the specific use or clearly states broad consent terms for future research.
  • Biobanks and MTAs: Describe governance, access conditions, Material Transfer Agreements, and anonymization level.
  • Genomic data: Follow field norms for controlled access (e.g., dbGaP/ENA-EGA equivalents) and address re-identification risks.

5.6 Animal Research and Welfare

  • Ethics approval: Animal studies require prior approval from an accredited committee. State the committee, approval identifier (if issued), and date.
  • 3Rs—Replacement, Reduction, Refinement: Describe justification for animal use, humane endpoints, and steps to minimize suffering.
  • Care and housing: Report species/strain, sex, age, housing conditions, anesthesia/analgesia, and euthanasia methods compliant with recognized guidelines.
  • Wildlife and field studies: Confirm permits; describe capture/handling methods, release, and post-procedure monitoring.
  • ARRIVE-aligned reporting: Provide group sizes, randomization, blinding, and statistical methods.

5.7 Fieldwork, Environmental, and Cultural Heritage Research

  • Permits and permissions: Confirm and cite permits for sampling, excavation, export/import, and access to protected areas.
  • Local collaboration and benefit sharing: Document equitable partnerships and capacity building where relevant.
  • Environmental impact and biosafety: Describe mitigation for ecological disturbance, invasive species risks, or pollutant handling.

5.8 Dual-Use Research of Concern (DURC) and Biosecurity

  • Risk identification: Authors must assess whether methods or results could be misused to cause significant harm (e.g., enhancing pathogen transmissibility or virulence, bypassing diagnostics, weaponization).
  • Risk mitigation: Describe safeguards, facility level (e.g., BSL), and redaction or delayed release if needed.
  • Compliance: Adhere to relevant laws on select agents, export controls, and shipping of biologicals. Editorial decisions may require modifications to methods or data sharing to reduce misuse risk.

5.9 High-Risk Methods and Hazardous Materials

  • Biosafety/chemical safety: State facility certifications and training. Report incident-prevention measures for toxins, radiological sources, nanomaterials, or high-powered lasers.
  • Engineering and cybersecurity: For systems with safety implications (e.g., autonomous robotics, critical infrastructure, offensive security tools), describe fail-safes, simulation-first testing, and coordinated disclosure practices.

5.10 Sensitive Data and Data Protection

  • Data minimization: Collect only necessary data; avoid storing directly identifiable data unless essential and consented.
  • Anonymization and access control: Use robust de-identification and access agreements; prefer controlled-access repositories for sensitive or rare-disease datasets.
  • Cross-border transfer: Disclose mechanisms for lawful transfer where applicable (e.g., Standard Contractual Clauses); do not expose participants to legal or social harm.

5.11 AI/ML Using Human or Sensitive Data

  • Dataset provenance: Disclose dataset sources, consent scope, licenses, and known biases.
  • Fairness and safety: Report performance across subgroups and limitations; avoid deployment claims not supported by evidence.
  • Reproducibility: Provide code, model cards, and evaluation protocols where legally and ethically permissible.

5.12 Deception, Waivers, and Debriefing

  • Use of deception: Allowed only with prior ethics approval where no alternative exists and risk is minimal. Provide debriefing procedures and explain any waiver of debriefing.
  • Consent waivers: Justify with reference to minimal risk and impracticability; include the approving body’s rationale.

5.13 Compensation and Undue Influence

  • Payments to participants: Must be proportionate to time and inconvenience, not coercive, and disclosed in methods or ethics statements.

5.14 Incidental Findings and Duty of Care

  • Clinical and non-clinical contexts: Describe procedures for managing incidental findings (e.g., genetic variants of clinical significance), including referral pathways where appropriate.

5.15 Images, Audio, and Identifiable Media

  • Explicit consent: Required for publication of images, audio, or video that could identify participants, including partially obscured faces or distinctive tattoos/scars.
  • Children: Obtain guardian consent and, where feasible, child assent. Avoid unnecessary identifiability.

5.16 Emergency, Conflict, and Disaster Settings

  • Context-appropriate oversight: Where formal IRBs are unavailable, document community or humanitarian review processes and ethical safeguards.
  • Do-no-harm priority: Extra caution for risks of reprisal, stigmatization, or surveillance; anonymize locations and traits when necessary.

5.17 What to Report in the Manuscript (Minimum Set)

  • Name of ethics committee/IRB and approval number or exemption with justification.
  • Consent procedures (including assent/guardian consent if applicable) and data-protection measures.
  • Trial registration ID for interventional studies and access to protocol.
  • Animal welfare approvals, permits, housing and care details, and humane endpoints.
  • Fieldwork permits, export/import licenses, and benefit-sharing agreements where relevant.
  • DURC/biosafety assessment and mitigation, including facility level and any justified redactions.
  • Data/code availability statements with repository links and access conditions.

5.18 Editorial Screening and Verification

  • Pre-review checks: Submissions are screened for ethics approvals, consent, trial registration, animal welfare statements, permits, and DURC flags.
  • Conditional acceptance: Editors may require additional documentation (e.g., blank consent forms, permit copies, IACUC/IRB letters).
  • Independent expertise: High-risk manuscripts may undergo specialist ethics or statistical review.

5.19 Non-Compliance and Remedial Actions

  • Before publication: Manuscripts with inadequate ethics documentation may be rejected or held pending correction.
  • After publication: Credible concerns trigger inquiry; editorial responses may include corrections, expressions of concern, or retractions. Institutions and funders may be notified where appropriate.
  • Sanctions: Repeated or serious breaches may result in submission bans for a defined period.

5.20 Record-Keeping and Retention

  • Authors should retain raw data, consent documents (or proof thereof), animal welfare logs, permits, and biosafety records for a period consistent with legal requirements and field norms.
  • On reasonable request during editorial evaluation or post-publication audit, authors must provide documentation sufficient to verify compliance.

5.21 Accessibility and Plain-Language Ethics Statements

  • Ethics statements must be written in clear, plain English. Avoid jargon; define acronyms at first use. Provide translations where this materially improves participant understanding or community engagement.